Clinical Trial Update: A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients [Phase 2]

View source ↗

Summary

This is a Phase 2 study evaluating NTQ5082 capsules for paroxysmal nocturnal hemoglobinuria. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• NTQ5082 capsules (NTQ5082)

Snippet

Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: ACTIVE_NOT_RECRUITING